Dial eyes aquisitions
This article was originally published in The Tan Sheet
Executive Summary
Firm looking to expand by purchasing new brand for its personal cleaning or household products divisions, CEO Herb Baum states at Banc of America securities Health Conference in San Francisco Sept. 16. Any acquisition "has to have an 18% or higher operating margin" to fit in company's current distribution system, exec notes, adding "we're good at liquid in a bottle." Baum also says international expansion is on hold after prior management team's ill-fated efforts in Argentina (1"The Tan Sheet," February 10, 2003, p. 10). "We're going to stay close to home...[as] there is a lot of growth left in North America," he asserts. Company is "comfortable" with third quarter and full-year guidance of $0.34 and $1.33 earning per share, respectively...
You may also be interested in...
Sales & Earnings In Brief
Bausch & Lomb: Worldwide lens care sales rose 8% to $121 mil. in Q4, led by ReNu products' double-digit gains in the Americas and Asia, according to Jan. 30 1company announcement. For the year, lens care revenues advanced 12% to $465.5 mil. Positive lens care performance, along with similar strong gains in contact lens and pharmaceuticals sales, helped power 9% overall sales increase to $1.81 bil. in 2002 versus the previous year, firm reports; full year net earnings rose to $72.5 mil. in 2002 from $21.2 mil. a year ago. B&L expects "low single-digit growth in" lens care sales in 2003. Additionally, Chairman & CEO Ronald Zarrella will oversee firm's Americas region commercial business until a successor is named for B&L exec Mark Sieczkarek, who left Jan. 31 "to pursue career opportunities elsewhere"...
IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: